



WATCH & RETURN

RCE 11614/18  
RECEIVED  
FEB 12 2003  
TECH CENTER 1600 2900

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**REQUEST  
FOR  
CONTINUED EXAMINATION (RCE)  
TRANSMITTAL**

Address to:  
Commissioner for Patents  
Box RCE  
Washington, DC 20231

|                        |                        |
|------------------------|------------------------|
| Application Number     | 09/692,807             |
| Filing Date            | 10/20/2000             |
| First Named Inventor   | Ghazwan Saleem Butrous |
| Art Unit               | 1614                   |
| Examiner Name          | Jones, Dwayne C.       |
| Attorney Docket Number | PC10370A               |

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. **Submission required under 37 CFR 1.114**

- a. ☐ Previously submitted
- i. ☐ Consider the amendment(s)/reply under 37 CFR 1.116 previously filed on \_\_\_\_\_  
(Any unentered amendment(s) referred to above will be entered).
- ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on \_\_\_\_\_
- iii. ☐ Other \_\_\_\_\_
- b. ☒ Enclosed
- i. ☒ Amendment/Reply
- ii. ☐ Affidavit(s)/Declaration(s)
- iii. ☐ Information Disclosure Statement (IDS)
- iv. ☐ Other \_\_\_\_\_

2. **Miscellaneous**

- a. ☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of \_\_\_\_\_ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(f) required)
- b. ☐ Other \_\_\_\_\_

3. **Fees** The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.

- a. ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 16-1445
- i. ☒ RCE fee required under 37 CFR 1.17(e) 02/11/2003 HBERHE 00000013 161445 09692807
- ii. ☐ Extension of time fee (37 CFR 1.136 and 1.17) 01 FC:1801 750.00 CH
- iii. ☒ Other Any other applicable fee
- b. ☐ Check in the amount of \$ \_\_\_\_\_ enclosed
- c. ☐ Payment by credit card (Form PTO-2038 enclosed)

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED**

|                   |                      |                                   |          |
|-------------------|----------------------|-----------------------------------|----------|
| Name (Print/Type) | A. Dean Olson        | Registration No. (Attorney/Agent) | 31,185   |
| Signature         | <i>A. Dean Olson</i> | Date                              | 2/4/2003 |

**CERTIFICATE OF MAILING OR TRANSMISSION**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

|                   |                       |      |          |
|-------------------|-----------------------|------|----------|
| Name (Print/Type) | Kelly A. Smith        | Date | 2/4/2003 |
| Signature         | <i>Kelly A. Smith</i> |      |          |

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Assistant Commissioner for Patents, Box RCE, Washington, DC 20231.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, Box RCE, Washington, D.C. 20231 on this 4<sup>th</sup> day of February, 2003.



*Kelly A. Smith*  
(Signature of person mailing)

Kelly A. Smith

(Typed or printed name of person)

RECEIVED  
FEB 13 2003  
TECH CENTER 1600/2900

#17/C  
JRP  
3/11/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Ghazwan Saleem Butrous et al

Examiner: Jones, Dwayne C.

APPLICATION NO: 09/692,807

Group Art Unit: 1614

FILED: October 20, 2000

TITLE: Treatment of Pulmonary Hypertension

SUBMISSION UNDER 37 C.F.R. 1.114

This is a submission accompanying a Request for Continued Examination being filed herewith in the above-captioned application. This application was allowed in an Official Action mailed on November 5, 2002 (claims 1-10 were allowed, with claims 11-20 having been canceled). The issue fee has not been paid in this application.

Please amend this application as follows:

IN THE CLAIMS

Please Cancel Claims 2-6.

Please Amend Claim 7 as follows:

7. (Twice Amended) A method according to claim 1 wherein the PDE5 inhibitor is administered orally.

(Please Amend Claim 8 as follows:)

8. (Amended) A method according to claim 1 wherein the PDE5 inhibitor is sildenafil citrate.

02/11/2003 NBERHE 00000013 09692807

01-FC:1801 750.00 CH  
02-FC:1202 1434.00 CH  
03-FC:1201 588.00 CH